MX2018007084A - Inhibidores de la tirosina quinasa de bruton y metodos de su uso. - Google Patents

Inhibidores de la tirosina quinasa de bruton y metodos de su uso.

Info

Publication number
MX2018007084A
MX2018007084A MX2018007084A MX2018007084A MX2018007084A MX 2018007084 A MX2018007084 A MX 2018007084A MX 2018007084 A MX2018007084 A MX 2018007084A MX 2018007084 A MX2018007084 A MX 2018007084A MX 2018007084 A MX2018007084 A MX 2018007084A
Authority
MX
Mexico
Prior art keywords
methods
bruton
inhibitors
tyrosine kinase
compounds
Prior art date
Application number
MX2018007084A
Other languages
English (en)
Inventor
Wei Chen
Jianmei Wei
Scott D Bembenek
James P Edwards
Jennifer D Venable
John J M Wiener
Kevin Kreutter
Zheng Zhang
Mark S Tichenor
Genesis M Bacani
Zhu Yaoping
Kun Xiao
Li Gang
Arora Nidhi
Kent Barbay Joseph
Cai Min
Pooley Deckhut Charlotte
Ghosh Brahmananda
Wu Yao
Zhang Feihuang
Hao Baoyu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2018007084A publication Critical patent/MX2018007084A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La presente descripción se refiere a compuestos de la fórmula I y métodos para su uso y preparación, así como composiciones que comprenden compuestos de la fórmula I. (ver Fórmula).
MX2018007084A 2015-12-10 2016-12-09 Inhibidores de la tirosina quinasa de bruton y metodos de su uso. MX2018007084A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562265780P 2015-12-10 2015-12-10
PCT/US2016/065964 WO2017100668A1 (en) 2015-12-10 2016-12-09 Inhibitors of bruton's tyrosine kinase and methods of their use

Publications (1)

Publication Number Publication Date
MX2018007084A true MX2018007084A (es) 2018-11-09

Family

ID=57681785

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007084A MX2018007084A (es) 2015-12-10 2016-12-09 Inhibidores de la tirosina quinasa de bruton y metodos de su uso.

Country Status (16)

Country Link
US (3) US10689396B2 (es)
EP (1) EP3386992B1 (es)
JP (2) JP7110097B2 (es)
KR (1) KR20180094514A (es)
CN (2) CN113105475B (es)
AR (1) AR107041A1 (es)
AU (1) AU2016366546B2 (es)
BR (1) BR112018011525B1 (es)
CA (1) CA3007993C (es)
EA (1) EA038031B1 (es)
IL (1) IL259862B (es)
JO (1) JO3793B1 (es)
MX (1) MX2018007084A (es)
TW (1) TWI739779B (es)
UY (1) UY37016A (es)
WO (1) WO2017100668A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
EP3596087A1 (en) * 2017-03-15 2020-01-22 Janssen Sciences Ireland Unlimited Company Methods of selective aryl- and heteroaryl-nitrogen bond formation
CN110028525A (zh) * 2018-04-13 2019-07-19 太仓运通新材料科技有限公司 一种2-氟磷酰基乙酸三乙酯的合成方法
CA3116141C (en) 2018-12-06 2023-09-05 Daiichi Sankyo Company, Limited Cycloalkane-1,3-diamine derivative
WO2021043200A1 (zh) * 2019-09-04 2021-03-11 正大天晴药业集团股份有限公司 一种喹唑啉衍生物的制备方法及其结晶
CN111635368B (zh) * 2020-06-12 2021-06-29 东莞市东阳光仿制药研发有限公司 一种胺化合物的制备方法
CN114478346A (zh) * 2021-12-31 2022-05-13 和鼎（南京）医药技术有限公司 一种制备乌帕替尼中间体的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3112415A1 (de) 1981-03-28 1982-10-07 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur chlorierung von cyclischen amiden und cyclischen vinylogen amiden
US5430150A (en) 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
US5300478A (en) 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
JP2008513463A (ja) 2004-09-15 2008-05-01 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ チアゾロピリジンキナーゼ阻害剤
WO2006118749A1 (en) * 2005-05-04 2006-11-09 Janssen Pharmaceutica, N.V. Thia-tetraazaacenaphthylene kinase inhibitors
US7605154B2 (en) 2005-08-08 2009-10-20 Janssen Pharmaceutica N.V. Substituted Thiazolo [4,5-d]pyrimidines as protein kinase inhibitors
WO2007092879A2 (en) * 2006-02-08 2007-08-16 Janssen Pharmaceutica, N.V. Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
EP2081435B1 (en) 2006-09-22 2016-05-04 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
US8598174B2 (en) * 2008-11-12 2013-12-03 Genetech, Inc. Pyridazinones, method of making, and method of use thereof
WO2011133609A2 (en) 2010-04-19 2011-10-27 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of btk inhibitors
FR2978441A1 (fr) 2011-07-25 2013-02-01 Diverchim Nouveaux analogues de ceramides, leurs procedes de preparation et leurs applications dans les compositions pharmaceutiques et cosmetiques
DK2970291T3 (da) 2013-03-15 2022-08-01 Janssen Pharmaceutica Nv Fremgangsmåder og mellemprodukter til fremstilling af et medikament
MX370103B (es) * 2013-12-11 2019-12-02 Biogen Ma Inc Compuestos de biarilo utiles para el tratamiento de enfermedades humanas en oncologia, neurologia e inmunologia.
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
JO3794B1 (ar) * 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
WO2018103060A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
WO2018103058A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use

Also Published As

Publication number Publication date
CN113105475A (zh) 2021-07-13
US20190284204A1 (en) 2019-09-19
TW201734020A (zh) 2017-10-01
AR107041A1 (es) 2018-03-14
IL259862B (en) 2022-04-01
US10689396B2 (en) 2020-06-23
CA3007993A1 (en) 2017-06-15
IL259862A (en) 2018-07-31
CA3007993C (en) 2024-01-16
US10800792B2 (en) 2020-10-13
CN109071563A (zh) 2018-12-21
EP3386992B1 (en) 2019-11-27
US20190284203A1 (en) 2019-09-19
BR112018011525B1 (pt) 2023-10-24
US20170283431A1 (en) 2017-10-05
JP2018536684A (ja) 2018-12-13
UY37016A (es) 2017-06-30
KR20180094514A (ko) 2018-08-23
JP2022141851A (ja) 2022-09-29
TWI739779B (zh) 2021-09-21
US10822348B2 (en) 2020-11-03
CN113105475B (zh) 2022-09-09
AU2016366546B2 (en) 2021-08-12
EA038031B1 (ru) 2021-06-25
EA201891379A1 (ru) 2018-12-28
AU2016366546A1 (en) 2018-05-31
EP3386992A1 (en) 2018-10-17
JP7471348B2 (ja) 2024-04-19
WO2017100668A1 (en) 2017-06-15
JP7110097B2 (ja) 2022-08-01
BR112018011525A2 (pt) 2018-11-21
JO3793B1 (ar) 2021-01-31

Similar Documents

Publication Publication Date Title
JO3794B1 (ar) المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
MX2020001598A (es) Inhibidores selectivos de proteína arginina metiltransferasa 5 (prmt5).
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
MX2018007084A (es) Inhibidores de la tirosina quinasa de bruton y metodos de su uso.
TN2018000276A1 (en) Inhibitors of receptor-interacting protein kinase 1.
NZ729603A (en) Heteroaryl compounds as btk inhibitors and uses thereof
MD4650B1 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
PH12016500531A1 (en) Compound inhibiting activities of btk and/or jak3 kinases
MD4800C1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
MY179781A (en) Biaryl inhibitors of bruton's tyrosine kinase
MX2017003930A (es) Derivados de aminotriazina utiles como compuestos inhibidores de la cinasa de union a tank.
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
EA201492056A1 (ru) Пиримидиниловые ингибиторы тирозинкиназы
EA201692525A1 (ru) Замещенные соединения [1,2,4]триазола и имидазола в качестве фунгицидов
MX2022010755A (es) Inhibidores de quinasa y usos de los mismos.
EA033238B1 (ru) Новые производные тиенопиримидина в качестве ингибиторов nik
MX2020006596A (es) Hidroxiisoxazolinas y derivados de estos.
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
EA201692289A1 (ru) Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов
MX2019010913A (es) Analogos de deutetrabenazina, su preparacion y uso.
EA201600002A1 (ru) Производные пролекарства замещенных триазолопиридинов